EU health chief to probe effects of Trump’s drug pricing push
EU’s scrutiny of US policy impact
Poinews.com – The European Commission is set to investigate the consequences of U.S. President Donald Trump’s initiative to standardize drug prices across developed nations through MFN pricing. This policy aims to align pharmaceutical costs with the lowest rates among global partners, prompting concerns over its influence on Europe’s pharmaceutical landscape.
Drug launches in the EU have seen a notable decline, with a 35% reduction observed in the 10 months following Trump’s May executive order. The analysis, shared by Reuters in March, highlights this trend as a key focus for the EU’s health ministers, who seek clarity on the policy’s broader implications.
“We want to be quick, meaning I still want to do it before the summer,” the commissioner said.
Trump’s directive and market dynamics
Trump’s May 2026 executive order compelled pharmaceutical firms to adjust pricing strategies in line with those of major trading partners. As the world’s largest market for prescription drugs, the U.S. accounts for over half of global demand, giving companies leverage to either increase prices or delay product releases in smaller markets like Europe.
Health ministers are now examining how MFN pricing affects new product introductions, potential market exits by manufacturers, and access to cutting-edge treatments. The EU executive seeks to understand the policy’s ripple effects, particularly its influence on pricing trends and launch timelines.
“This is the assignment that we take back home,” he said.
Urgency in addressing market concerns
With time pressing, the EU is determined to evaluate the extent to which MFN pricing disrupts its pharmaceutical sector. The goal is to determine if the policy has led to slower product introductions, inflated costs, or diminished availability of new medications in the bloc.
